Optimization of PSMA-I&T radiolabeling with 177Lu
DOI:
https://doi.org/10.15392/2319-0612.2024.2690Keywords:
Radiolabeling 1, PSMA I&T 2, Optimization 3, Lutetium-177 4Abstract
Prostate cancer (PCa) is the second most common type of cancer in men and the fifth cause of mortality worldwide. Metastatic prostate cancer is associated with a poor prognosis and decreased life expectancy. Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is anchored in the epithelial prostate cell membrane, overexpressed in prostate cancer, increased in metastatic castration-resistant prostate cancer (mCRPC) patients and with a consensus that its expression level is correlated to the malignancy of the disease. 177 Lu-PSMA-I&T stands out as a promissor radiopharmaceutical for therapy of prostate cancer and currently is being described based on this specifically bind to PSMA with the Glu-urea-Lys pharmacophoric group. This present work aimed to determine the most favorable conditions for labeling PSMA I&T with carried-added lutetium-177, evaluating the influence of molar ratio, pH, temperature and reaction time, to obtain the radiopharmaceutical with high radiochemical purity (%RP ≥95%), avoiding the final purification step. The percentage of radiochemical purity was evaluated by High Pressure Liquid Chromatography (HPLC) and Thin Layer Chromatography on silica gel 60 plate (TLC-SG). The results obtained with this work made it possible to define and standardize the best condition for PSMA I&T radiolabeling with carried-added 177Lu.
Downloads
References
[1] GLOBOCAN 2022. Global Cancer Observatory. Disponível em: https://gco.iarc.fr. Acesso em 20 Mar. 2024.)
[2] MORBECK, I. A. P., GADIA, R., CHAVES, N. R., SANTOS, M. Câncer de próstata. Diretrizes Oncológicas. p. 1-24, 2019. Disponível em: https://diretrizesoncologicas.com.br/wpcontent/uploads/2019/10/Diretrizes-oncologicas_separata_Prostata.pdf. Acesso em 20 mar 2024.
[3] CHATALIC, K. LS. et al., Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen, Targeted Theranostic Agent Theranostics, vol. 6, 18387640. p. 849-861, 2016. DOI: https://doi.org/10.7150/thno.14744
[4] BAUM, R.P. et al., 177Lu -Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy, Journal of Nuclear Medicine, vol. 57, p. 1006–1013, 2016. DOI: https://doi.org/10.2967/jnumed.115.168443
[5] WEINEISEN, M et. al., 68Ga- and 177Lu -Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies, Journal of Nuclear Medicine, vol. 56, p.1169–1176, 2015. DOI: https://doi.org/10.2967/jnumed.115.158550
[6] VYAS M., LIM, R., FAGAN, J., CHANDRASHEKCAR, R., Stability matters: Radiochemical Stability of Therapeutic Radiopharmaceutical 177Lu -PSMA I&T., Journal of Nuclear Medicine Technology, vol. 50, p. 244-247, 2022. DOI: https://doi.org/10.2967/jnmt.121.262423
[7] MALIK, N. et al., Radiofluorination of PSMA-HBED via AI(18)F(2+) Chelation and Biological Evaluations In Vitro. Molecular Imaging and Biology, vol.17, p. 777-785, 2015. DOI: https://doi.org/10.1007/s11307-015-0844-6
[8] RUANGMA A., KIJPRAYOON, S., NGOKPOL, S., PSMA for PET imaging of prostate cancer. The Bangkok Medical Journal, vol. 14, p. 95, 2018. DOI: https://doi.org/10.31524/bkkmedj.2018.09.016
[9] DI LORIO, V. et al., Production and Quality Control of [177Lu] Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials. Molecules, vol.27, p.4143-4158, 2022. DOI: https://doi.org/10.3390/molecules27134143
[10] CHAKRABORTY S, S., et al., Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu -labeled PSMA inhibitor. Journal of Labelled Componds and Radiopharmaceutical, vol. 59, p. 364-371, 2016. DOI: https://doi.org/10.1002/jlcr.3414
[11] ZALUTSKY, M.R. Radionuclide Therapy. In: VÉRTES, A.; NAGY, S.; ZOLTÁN, K. Handbook of Nuclear Chemistry. Netherlands: Kluwer Academic Publishers, v. 4, p. 315-348, 2003.
[12] BOAS, C. A. W. V., et al., In vitro and in vivo response of PSMA-617 radiolabeled with CA and NCA lutetium-177, Applied Radiation and Isotopes, vol. 180, p 1-7, 2022. DOI: https://doi.org/10.1016/j.apradiso.2021.110064
[13] DASH, A.; PILLAI, M.R.A.; KNAPP, F.F.JR.; Production of (177) Lu for Targeted Radionuclide Therapy: Available Options. Nuclear Medicine and Molecular Imaging, Vol 49, p. 85-107, 2015. DOI: https://doi.org/10.1007/s13139-014-0315-z
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2024 Luiza Mascarenhas Balieiro, Maria das Dores Domingos, Luana Pereira da Silva, Joel Mendes dos Santos, Margareth Mie Nakamura Matsuda, Luis Alberto Pereira Dias, Elaine Bortoleti de Araújo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
How to Cite
